Triple intrathecal therapy

DRUG2 trials

Sponsors

Therapeutic Advances in Childhood Leukemia Consortium, Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Conditions

Allergy to Native e.Coli AsparaginaseAllergy to PEG e.Coli AsparaginaseChildhood Acute Lymphoblastic LeukemiaRelapsed Acute Lymphoblastic Leukemia

Phase 1

Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)

TerminatedNCT00928200

Therapeutic Advances in Childhood Leukemia ConsortiumAllergy to Native e.Coli Asparaginase, Allergy to PEG e.Coli Asparaginase, Relapsed Acute Lymphoblastic Leukemia

Start: 2009-04-13End: 2010-06-04Updated: 2019-02-19

Unknown Phase

Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2008

Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyChildhood Acute Lymphoblastic Leukemia

Start: 2008-02-29End: 2020-07-31Target: 3000Updated: 2020-02-05